Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a serious ...

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...

Novo Nordisk share price rose nearly 5% on August 18, 2025. The hike came after the US Food and Drug Administration granted ...

Novo Nordisk stock was jumping Monday after the company said late Friday that its weight-loss medicine Wegovy had been approved to treat a serious form of liver disease. It’s a welcome boost for the ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Shares of Novo Nordisk (NVO) are rising early Monday after the US Food and Drug Administration approved Wegovy to treat ...

Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...